enGene Holdings Inc. (NASDAQ:ENGN) Given Average Recommendation of “Hold” by Brokerages

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been given an average rating of “Hold” by the fourteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $11.0455.

Several research analysts recently issued reports on the company. UBS Group reduced their target price on enGene from $9.00 to $2.00 and set a “neutral” rating on the stock in a research report on Thursday, May 14th. Morgan Stanley downgraded enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price target for the company. in a report on Thursday, June 18th. Guggenheim lowered enGene from a “buy” rating to a “neutral” rating in a research note on Thursday, May 7th. Weiss Ratings downgraded shares of enGene from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 15th. Finally, WBB Securities assumed coverage on shares of enGene in a research report on Monday, April 13th. They issued a “buy” rating and a $21.50 price objective for the company.

enGene Stock Down 1.0%

ENGN traded down $0.02 during trading on Friday, hitting $1.90. The stock had a trading volume of 1,096,343 shares, compared to its average volume of 1,116,624. The stock has a 50 day simple moving average of $2.09 and a two-hundred day simple moving average of $6.35. The company has a debt-to-equity ratio of 0.10, a quick ratio of 12.57 and a current ratio of 12.57. enGene has a twelve month low of $1.40 and a twelve month high of $12.25. The company has a market capitalization of $127.28 million, a PE ratio of -0.88 and a beta of -0.28.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Monday, June 15th. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.91. During the same period last year, the company earned $0.51 EPS. On average, research analysts predict that enGene will post -1.84 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Cresset Asset Management LLC purchased a new stake in shares of enGene during the second quarter valued at $36,000. Paloma Partners Management Co acquired a new position in shares of enGene in the 2nd quarter valued at $38,000. Raymond James Financial Inc. raised its stake in enGene by 383.6% in the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after acquiring an additional 7,932 shares during the last quarter. Hudson Bay Capital Management LP purchased a new position in enGene in the 3rd quarter worth $76,000. Finally, PFS Partners LLC lifted its position in enGene by 22.2% during the 4th quarter. PFS Partners LLC now owns 11,000 shares of the company’s stock worth $99,000 after acquiring an additional 2,000 shares during the period. Institutional investors and hedge funds own 64.16% of the company’s stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.